Christie NHS Foundation Trust


Klinik

Standort der Organisation:
Manchester, Großbritannien (UK)


Publikationen in Kooperation mit FAU-Wissenschaftlerinnen und Wissenschaftlern


Barnes, P.W., Williamson, C.E., Lucas, R.M., Robinson, S.A., Madronich, S., Paul, N.D.,... Zepp, R.G. (2019). Ozone depletion, ultraviolet radiation, climate change and prospects for a sustainable future. Nature Sustainability. https://dx.doi.org/10.1038/s41893-019-0314-2
Lamarca, A., Ronot, M., Moall, S., Crona, J., Opalinska, M., Lopez, C.,... Dromain, C. (2019). Tumour Growth Rate (TGR) in Neuroendocrine Tumours (NETs): Changes Following Systemic Treatment; the GREPONET-2 Study. In NEUROENDOCRINOLOGY (pp. 137-137). BASEL: KARGER.
Lamarca, A., Crona, J., Ronot, M., Opalinska, M., Lopez Lopez, C., Pezzutti, D.,... Dromain, C. (2019). Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients’ Outcome in Neuroendocrine Tumors (NET)—The GREPONET Study. Oncologist. https://dx.doi.org/10.1634/theoncologist.2018-0672
Crona, J., Lamarca, A., Ronot, M., Opalinska, M., Lopez Lopez, C., Pezzutti, D.,... Dromain, C. (2018). Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study. (pp. 171-171).
Lamarca, A., Crona, J., Ronot, M., Opalinska, M., Lopez Lopez, C., Pezzutti, D.,... Dromain, C. (2018). Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients' Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study. (pp. 178-178).
Ferreri, A.J.M., Cwynarski, K., Pulczynski, E., Fox, C.P., Schorb, E., La Rosee, P.,... Illerhaus, G. (2017). Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal L. Lancet Haematology, 4(11), e510-e523. https://dx.doi.org/10.1016/S2352-3026(17)30174-6
Ferreri, A.J.M., Cwynarski, K., Pulczynski, E., Ponzoni, M., Deckert, M., Politi, L.S.,... Illerhaus, G. (2016). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematology, 3(5), e217-27. https://dx.doi.org/10.1016/S2352-3026(16)00036-3
Marx, A., Stroebel, P., Badve, S.S., Chalabreysse, L., Chan, J.K.C., Chen, G.,... Travis, W.D. (2014). ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. Journal of Thoracic Oncology, 9(5), 596-611. https://dx.doi.org/10.1097/JTO.0000000000000154

Zuletzt aktualisiert 2017-16-02 um 08:41